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Abstract
  
 Neuroendocrine tumors (NETs), previously known as carcinoid tumors, are a 
heterogeneous group of neoplasms which originate from cells of the endocrine or nervous 
system with an overall incidence of 1–5 cases per 100,000 individuals per year. Recent 
studies showed that their incidence has dramatically increased worldwide over the last 
few years. The majority of NETs overexpress the somatostatin receptors (SSTRs) in tumor 
cells which are further being used as the important targets for therapy purposes using 
somatostatin analogs (SSAs) such as octreotide and lanreotide. Like native somatostatin, 
SSAs bind to SSTRs and induce a range of cellular effects, including antitumor activity. 
Antitumor activity of SSAs and their high binding properties for the SSTRs have become 
valuable tools for developing advanced treatment of NETs. Consequently, SSAs have been 
used widely in routine clinical practice, especially for treatment of various types of NETs. 
Despite treatment using SSAs have made a positive contribution, recent development 
suggests that the used of SSAs in combination with chemotherapy or peptide receptor 
radionuclide therapy (PRRT) can improve clinical outcome in patients with NETs. This 
review provides an overview of the recent trend in the treatment of NETs using SSAs, 
their clinical achievements in the last few years and their potential applications in the 
future.   
Keywords: neuroendocrine tumors, treatment, somatostatin analogs, chemotherapy, 
PRRT
INTRODUCTION
 Neuroendocrine tumors (NETs), previously 
known as carcinoid tumors are a heterogeneous 
group of neoplasms which originate from cells of 
the endocrine or nervous system and may derive 
from the embryonic neural crest cells of several 
organs (Kaltsas, et al., 2004; Gould, et al., 2013; 
Al-Chalabi, et al., 2018). Most NETs are located in 
the gastrointestinal tract and the lung and occasion-
ally occur in the pancreas, head and neck region, 
prostate, ovary, testis and liver (Gabriel, et al., 2007; 
Modlin, et al., 2003). Interestingly, NETs can also 
be found in the breast tissue, although the incidence 
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is rare, around 0.27–0.50% (Adams, et al., 2014). 
Despite pathophysiological mechanism underlying 
NETs is still largely unknown, study at the genomic 
level has suggested the important role of transcrip-
tome, micro–RNome and exome in the regulation 
of secretory and proliferative mechanism of NETs 
(Kidd, et al., 2015). In addition, several hypotheses 
including dysregulation of the phosphatidylinosi-
tol-3-kinase (PI3K)/AKT and the mammalian target 
of rapamycin (mTOR) signaling have been linked 
with the pathogenesis of these tumors (Boora, et al., 
2015).
 NETs are characterized by their ability to 
overexpress the neurosecretory granules that con-
tain numerous bioactive compounds such as pep-
tides, hormones, kinins, vasoactive amines, and 
endorphins which cause characteristic hormonal 
syndromes leading to several clinical signs and 
symptoms (Gould, et al., 2013; Yao, et al., 2008). 
A variety of clinical symptoms in NETs patients 
may include flushing, diarrhea, bronchospasm, 
hepatomegaly, sweating, hemoptysis, wheeze, 
hypotension and anxiety (Bodei, et al., 2014; Ja-
yasena, et al., 2013). Additionally, local symptoms 
induced by tumor aggregates (e.g., pain, bleeding, 
obstruction, and perforation) are frequently ob-
served in patients with advanced NETs (Frilling, et 
al., 2014). Importantly, the majority of NETs over-
express somatostatin receptors (SSTRs), mainly 
types 2 and 5 on their cell surfaces which are further 
being used as the important targets for therapy of 
patients with NETs and neuroendocrine neoplasias 
(NENs) (Kayani, et al., 2008; García-Talavera, et 
al., 2014; Fani, et al., 2017).
 It was previously believed that NETs are 
relatively slow growing and uncommon in hu-
mans with an overall incidence of 1–5 cases per 
100,000 per year (Amr, et al., 2015; van der Zwan, 
et al., 2013). However, a large number of reports 
showed that their incidence has dramatically in-
creased worldwide over the last few years. Accord-
ing to Surveillance Epidemiology and End Results 
(SEER) database, in 1973 the incidence of NETs 
was 1.09 per 100,000. This incidence increased 5–
fold in 2004 to 5.25 per 100,000 (Yao, et al., 2008). 
Furthermore, the project of surveillance of rare can-
cer (RARECARE) also found that the overall inci-
dence rate of NETs in Europe was 25 per 1,000,000 
during 1978–2002 (van der Zwan, et al., 2013).
 In the United Kingdom during 1971–2006, 
the incidence of NETs rose approximately 2.9– to 
3.8–fold (Frilling, et al., 2014). In particular, since 
the 1970s, the incidence of pancreatic endocrine tu-
mor (pNET) also increased annually from 0.32 to 
0.43 per 100,000 (Dilz, et al., 2015). Korse et al. re-
ported that the incidence of grade 1 NET (G1NET) 
in the Netherlands has progressively increased from 
2 per 100,000 in 1990 to 3 per 100,000 in 2010 and 
the large increase experienced by grade 2 NET 
(G2NET) from 0.01 per 100,000 in 1990 to 0.2 
per 100,000 in 2010 (Korse, et al., 2013). Another 
report showed that in Denmark, the incidence of 
NETs increased by 2–fold in men from 0.24 to 0.53 
per 100,000 per year (Skuladottir, et al., 2002). In 
Australia, the annual incidence of NETs increased 
approximately 2–fold from 1.7 (1980–1989) to 3.3 
(2000–2006) (Luke, et al., 2010).
 An important progress in the field of NETs 
management was the recent development of several 
therapeutic strategies that exploit the role of soma-
tostatin and its analogs, which seemed to become an 
attractive option in routine clinical practice (Rai, et 
al., 2015). Although the application of somatostatin 
analogs (SSAs) is a well established treatment for 
various types of NETs, the combination of SSAs 
with other therapies has not been extensively stud-
ied. Thus, current development in preclinical and 
clinical studies of SSAs for treatment of NETs and 
their combination with chemotherapy and peptide 
receptor radionuclide therapy (PRRT) as well as the 
potential future of therapeutic applications are dis-
cussed here. 
Somatostatin and Somatostatin Receptors 
(SSTRs) 
 Somatostatin, also known as somatotropin 
release–inhibiting factor is a naturally occurring 
peptide hormone that controls the endocrine and 
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exocrine secretion and inhibits proliferation of nor-
mal and tumor cells (Susini, et al., 2006). The role 
of somatostatin in NETs is mediated through its in-
teraction with one of five SSTRs (Baldelli, et al., 
2014). Therefore, the correlation of NETs with the 
SSTRs has raised significant interest among clini-
cians and scientists worldwide, in particular for de-
veloping a more suitable treatment for the patients 
with SSTR–expressing NETs, informed by the wide 
range of pharmacological studies reported in recent 
years (Chalabi, et al., 2014).
 Based  on  the  correlation  study  of  mRNA 
and   maximum  standardized  uptake    value 
(SUVmax), SSTR–1 was the highest level of recep-
tor in the normal human tissue. Similarly, SSTR–2 
was nearly as high as SSTR–1. Other somatostatin 
receptors showed lower levels and SSTRs–4 is the 
lowest abundance receptor (Boy, et al., 2011). Sev-
eral studies have revealed that SSTRs abundance in 
NETs were significantly higher than normal tissues. 
In vivo biodistribution study using SSA agonist 
radiotracer 99mTc–[ethylenediamine-N,N′–diacetic 
acid/tricine/6-hydrazinopyridine-3-carboxylic acid 
(HYNIC0)] 1-Nal3, Thr8–octreotide (99mTc–[EDDA/
tricine/HYNIC]–NATE) demonstrated that SSTRs 
accumulation in rat bearing AR4–2J tumor was 
higher than blood, adrenals, spleen, stomach, intes-
tine, liver, lung, heart and bone after 1 and 4 hours 
injection, respectively (Gandomkar, et al., 2007). 
Moreover, it was reported that the biodistribution 
and accumulation of SSA antagonist radiotracer 
111In–1,4,7,10-tetraazacyclododecane–1,4,7,10–
tetraacetic acid (DOTA)–sst2–antagonist (ANT) 
(111In–DOTA–sst2–ANT) was higher in NET than 
other organs for 4 hours after injection (Wang, et 
al., 2012). 
 In many cases, NETs are express varying 
concentrations of SSTRs. Thus, the abundance of 
SSTR is depending on the origin, stage, and the 
type of tumor. SSTR–1 can be found in high con-
centration in prostate cancer tissues, although other 
SSTRs are present. Generally, all SSTR subtypes are 
expressed in NETs, however, SSTR–2 was found in 
higher level compared to others subtypes (Cakir, et 
al., 2010). The significant expression of SSTR–2 
and SSTR–5 in humans was reported in 108 endo-
crine pituitary tumors study. This study revealed 
that 93% of growth hormone tumors expressed 
SSTR–2 and 83% expressed SSTR–5 (Chinezu, et 
al., 2014). Other tumors such as thyroid, melanoma 
and gastrointestinal carcinoid expressed all five re-
ceptors although in varying level. In specific tumors 
such as hepatocellular carcinoma, the SSTR–5 ex-
pression was dominant (Blaker, et al., 2004).
Figure 1. Chemical structures of the native somatostatin. R = H (somatostatin–14); R = H–serine–alanine–aspar-
agine–serine–asparagine–proline–alanine–methionine–alanine–proline–arginine–glutamic acid–arginine–lysine (so-
matostatin–28) (Weckbecker, et.al., 2003)
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NETs Treatment using Somatostatin Analogs 
(SSAs)
 Initially, surgery is the established treat-
ment and has been used for a long time to remove 
NETs and prolong survival rate in patients (Kaltsas, 
et al., 2004; Ha, et al., 2012; Walter, et al., 2012). 
This treatment has also been used in patients with 
liver  metastasis  which  arises  from  carcinoid 
tumors (Pathak, et al., 2013; Nave, et al., 2001). 
A study showed that surgery for cytoreduction of 
NET metastasis has been associated with the dura-
tion of survival, for instance Mayo and colleagues 
reported that a 5–year survival and 10–year survival 
of 74% and 51% respectively, were achieved by the 
patients after liver–directed surgery for metastatic 
NETs (Mayo, et al., 2010). However, the surgery 
outcome is directly depending on the stage of tu-
mors (tumor size) (Ha, et al., 2012), tumor location, 
and involvement of surrounding tissues (Oberg, 
2012).
 Another treatment to destroy the tumor ag-
gregates of NETs is chemotherapy. This approach 
has traditionally been used in a variety of NETs. 
The use of combination chemotherapeutic agents, 
such as 5–fluorouracil and streptozotocin generated 
an overall disease control (ODC) rate of 83.3% in 
96 patients with pNET (Dilz, et al., 2015). More-
over, single agent for NETs therapy such as adri-
amycin, 5–fluorouracil, actinomycin-D and dacar-
bazine demonstrated an objective response (OR) of 
21, 26, 6, and 13%, respectively (Moertel, 1983). In 
NETs, the efficacy of chemotherapy is always asso-
ciated with the types of NETs, for example, pNETs 
have a high sensitivity to chemotherapy, whereas 
gastrointestinal NETs (GINETs) are often resistant 
to chemotherapy treatment (Walter, et al., 2012). 
Moreover, due to the toxicity, some chemotherapy 
agents may be not suitable for some patients and 
therefore limit their use in clinical setting (Peixoto, 
et al., 2014).       
 NETs management has evolved over the 
last few decades due to the increasing understand-
ing of their tumor biology and molecular regulation. 
Some studies have been showed that somatostatin 
has a broad range of biological functions such as 
antiproliferative regulation (Owonikoko, et al., 
2019), induction of apoptosis to inhibit tumor cell 
proliferation and angiogenesis (Rai, et al., 2015), 
regulation of endocrine and exocrine secretions in-
cluding growth hormone in acromegaly, inhibition 
the secretion of insulin and glucagon (Murray, et 
al., 2015) and inhibition of the release of gastroin-
testinal hormones and thyroid-stimulating hormone 
(Theodoropoulou, et al., 2013). 
 The inhibitory effects of several hormones 
and growth factors as well as tumors growth fac-
tor are making somatostatin as a crucial tool for 
developing advanced treatments of patients with 
NETs. Commonly, the effect of somatostatin as an 
antitumor in NETs is based on their capability to 
exert antitumor activity through direct and indirect 
mechanisms (He, et al., 2019). The direct mecha-
nisms include some biological processes in the cell 
such as induction pertussis toxin–sensitive, G–pro-
tein-coupled receptor (GPCR) intracellular signals, 
proapoptotic effect, and inhibition cell cycle (Cha-
labi, et al., 2014). One of the main processes in the 
indirect mechanisms of somatostatin is the inhi-
bition of growth factor receptor signaling. In this 
process, protein tyrosine phosphatases (PTPs) has 
played an important role by dephosphorylating the 
growth factor in tyrosine kinase receptors (Theodo-
ropoulou, et al., 2013). 
 On the other hand, somatostatin also exerts 
a number of indirect antitumor mechanisms  such as 
inhibition of the secretion of hormones and growth 
factors, inhibition of the cell proliferation and an-
giogenesis by eliminating somatostatin receptor 
function, and modulation of the immune system 
to stimulate natural antitumor mechanism (Susini, 
et al., 2006; Chalabi, et al., 2014). However, so-
matostatin has a short half-life (t1/2) in vivo (1–3 
minutes), making it unsuitable for the treatment of 
NETs, hence some synthetic SSAs were developed 
including octreotide, lanreotide, vapreotide (Figure 
2) (Marciniak, et al., 2017). To date, SSAs have 
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been used to treat most NETs either for inhibiting 
the tumor growth or symptom relief (Cwikla, et al., 
2015; Maqsood, et al., 2019).
 Similar to native somatostatin, SSAs bind 
to SSTRs and induced a range of cellular effect, 
including antitumor activity (Sideris, et al., 2012). 
Octreotide was the first SSA approved and widely 
used for management of hormonal syndromes re-
sulting from NETs. This analog has a strong affin-
ity to SSTR–2 and SSTR–5 and showed antitumor 
properties in patients with NETs. Accumulating 
evidence showed octreotide long–acting repeat-
able (LAR) as well as lanreotide autogel (lanreo-
tide ATG) have strong efficacy and well tolerated 
in NET patients (Godara, et al., 2019). In a clinical 
study by Rinke, et al., it was clearly demonstrated 
that treatment of NETs patients using octreotide 
LAR resulted in a median time to tumor progres-
sion of 14.3 months, higher than placebo groups (6 
months). Additionally, stable disease was achieved 
in 66.7% of patients in the octreotide LAR group af-
ter 6 months of treatment. This number was higher 
than patients in placebo group (37.2%) (Rinke, et 
al., 2009). Antiproliferative effects of lanreotide 
ATG has also been demonstrated in the efficacy 
and safety study in 30 patients with well-differenti-
ated NETs. In this study, lanreotide ATG provided 
effective tumor stabilization in 24 patients (89%) 
and median progression–free survival (PFS) of 12.9 
months (Richard, 2013). 
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Figure 2. Chemical structure of 
several somatostatin SSAs 
(Gunther, et al., 2018).
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Peptide Receptor Radionuclide Therapy 
(PRRT)
 To date, some SSAs have also been ex-
ploited as PRRT for eradicating malignant cells in 
NETs. PRRT is a treatment that uses radioisotope 
attached to the SSA to deliver therapeutic dose 
of ionizing radiation to tumor cells (Dash, et al., 
2015). The illustration of the PRRT mechanism to 
eradicate tumor cells is shown in Figure 3. 
 In the past ten years, some PRRT SSTR–
targeting radionuclide therapies for clinical man-
agement of NETs were developed, including 90Y–
[DOTA0, Tyr3]–octreotide (90Y–DOTA–TOC), 
90Y–[DOTA0, Tyr3]–octreotate (90Y–DOTA–TATE), 
177Lu–[DOTA0, Tyr3]–octreotide (177Lu–DOTA–
TOC), 177Lu–[DOTA0, Tyr3]–octreotate (177Lu–
DOTA–TATE) (Gabriel, et al., 2007; Baum, et al., 
2015). The idea of using 90Y (t1/2 = 64.6 hours) and 
177Lu (t½ = 160.8 hours) as radionuclide therapy is 
based on their energy characteristics. 177Lu emits β– 
energy of 149 keV and maximum particle range of 
1.5  mm,  and  therefore  suitable  for  destroying 
small lesions of NETs. In contrast, 90Y emits higher 
β– energy of 2.28 MeV and maximum particle 
range of  12  mm  which  more  suitable  for  the 
eradication of bulky NETs. These characteristics 
make them well  suited  for  PRRT  of  NETs  (Perk, 
et  al.,  2005; Garkavij, et al., 2010; Fenwick, et 
al., 2014). However, the combination of 90Y and 
177Lu may be the most effective for NETs treatment 
(Kwekkeboom, et al., 2006). Some alternative radi-
onuclides (Table 1) can be considered for the treat-
ment of NETs.
 The growing number of studies indicates 
that various SSAs radiolabelled with 90Y and 177Lu 
have played an important role in NETs management 
strategy. For instance, 90Y–octreotide and 177Lu–oc-
treotate demonstrated OR rates of 15–35% (Baum, 
et al., 2015). Recent clinical studies indicated that 
PRRT can prolong the 5–year survival rate and im-
prove quality of life factors in a considerable number 
of NETs patients. Moreover, PRRT achieved higher 
median 5–year survival compared to patients with 
untreated, conventional chemotherapy, transarterial 
chemoembolization (TACE) and transarterial em-
bolization (TAE) (Bodei, et al., 2014). In particular, 
90Y has demonstrated significant contribution in the 
treatment of NETs as well as liver tumor without 
causing extreme dose to neighboring healthy tis-
sues (Fenwick, et al., 2014). A study showed that 
therapy outcome of NETs using 90Y–DOTA–TOC 
increased with adding of 131I–MIBG (Bushnell, et 
al., 2014). 
 In a more detailed study, it was shown that 
PRRT using 90Y–DOTA-TATE and 90Y–DOTA–
TOC in patients with progressive metastatic NETs 
Figure 3. The schematic diagram illustrated the role of PRRT in the treatment of NETs.
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were correlated with high values of positive re-
sponse (24.5%) and stable disease (47%). Those 
values contributed to significant overall survival 
(OS) in patients. This study also revealed that re-
nal toxicity was rare, however, the hematological 
toxicity was common (Vinjamuri, et al., 2013). 
Another clinical study showed that a single cycle 
of 5 GBq 90Y–DOTA–TATE was effective for treat-
ing metastatic NETs in the liver. Patient follow–up 
showed only single liver metastasis observed after 
12 months of PRRT treatment (Baum, et al., 2012).
 The current study also showed that 177Lu–
octreotate highly effective for treating advanced 
NETs of the small intestine and demonstrated stable 
disease in 47.5% patients and only 8.2% patients 
indicated with progressive disease (Sabet, et al., 
2015). The positive contribution of 177Lu–octreotate 
also reported by Ezziddin and co–workers with a 
median PFS and OS in advanced grade 1/2 pNETs 
were 34 and 53 months, respectively. Furthermore, 
the partial response, minor response, stable disease 
and progressive disease were observed in 60.3, 11.8, 
13.2, and 14.7% patients, respectively (Ezziddin, et 
al., 2014). Kwekkeboom, et al., reported that a high 
value of stable disease of gastroenteropancreatic 
NETs (GEPNETs) was achieved by 177Lu–DOTA–
TATE in 30 patients (40%) (Kwekkeboom, et al., 
2006). More recently, a study showed that longer 
OS was achieved in patients with bronchial NET 
or GEPNETs after PRRT with 177Lu–DOTA–TATE 
compared to control group (van der Zwan, et al., 
2019).  
 The used of 90Y and 177Lu in combination 
formula showed more advantages than single treat-
ment using 90Y or 177Lu. In the pre-clinical study us-
ing rats tumor model, remarkable antitumor activity 
was achieved by the combination of 90Y–SSA and 
177Lu–SSA (50% : 50%) compared to single treat-
ment using 90Y–SSA or 177Lu–SSA. This study also 
indicated that a combination of these radionuclides 
may become an effective strategy for eradication 
different size of tumor cells (de Jong, et al., 2005). 
Kunikowska and colleagues reported that the com-
bination of 90Y and 177Lu demonstrated longer OS 
in NETs patients than single radionuclide treatment. 
In this study, 25 patients were administered with 
90Y–DOTA–TATE (group A) and 25 patients were 
administered with the combination of 90Y/177Lu–
DOTA–TATE (1 : 1) (group B). It was observed 
that the median event–free survival (EFS) in group 
A and B were 21.4 and 29.4 months, respectively. 
It also showed that 64% of patients from group 
Table 1. Alternative radionuclides for PRRT.
Radionuclide Half-life (T1/2) Emissions Reference
111In 67.4 hours γ, e– Auger (Dash, et al. , 2015)
67Cu 61.9 hours β–, γ (Dash, et al. , 2015)
47Sc 82.1 hours β–, γ (Dash, et al. , 2015)
161Tb 165.6 hours β–, γ (Dash, et al. , 2015)
225Ac 240.0 hours α, β–, γ (Dash, et al. , 2015)
213Bi 0.77 hours α, β– (Dash, et al. , 2015)
64Cu 12.8 hours β–, β+ (Cremonesi, et al. , 2006)
166Ho 26.8 hours β (Cremonesi, et al. , 2006)
188Re 17.0 hours β– (Cremonesi, et al. , 2006)
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B experienced stable disease after 12 treatments, 
whereas only 52% from group A (Kunikowska, 
et al., 2011). The comprehensive clinical study of 
PRRT in NETs treatment involving 27 patients has 
been reported by Matovic. This study used three 
different  PRRTs: 90Y–DOTA–TOC, 177Lu–DOTA–
TATE, and the combination of 90Y–DOTA–TOC 
and 177Lu–DOTA¬TATE. It was concluded that the 
partial response, stable disease, and progressive 
disease were 25.9, 63.0, and 11.1%, respectively 
(Matovic, 2012).  
 The main challenge for developing PRRT 
is the appearance of side effects due to the radiation 
exposures which can affect the normal functions of 
several organs and tissues including kidney, blood, 
and bone marrow. Villard, et al., reported that after 
a four cycles of therapy with 90Y–DOTA–TOC, 15 
patients (6.3%) experienced transient hematologic 
toxicities and 1 patient was diagnosed with acute 
myeloid leukemia. Interestingly, only 11 patients 
(4.4%) experienced severe transient hematologic 
toxicities and negative myeloproliferative was ob-
served after radiotherapy using the combination of 
90Y–DOTA–TOC and 177Lu–DOTA–TOC (Villard, 
et al., 2012).  To minimize the side effects, the role 
of excretion organs is crucial to accelerate the elim-
ination of the radionuclide after the treatment. For 
example, the pathway involves reabsorption of the 
radionuclide by kidneys should be minimized. In 
order to overcome this issue, some organic com-
pounds such as gelofucine and amino acids (e.g., 
lysine and arginine) have been used to reduce ra-
dionuclide uptake by the kidney (Vinjamuri, et al., 
2013; Edgar, 2006).
Combined Therapy in NETs
 The use of SSAs in routine clinical prac-
tice as an extensive treatment modality has revolu-
tionized the management strategy of patients with 
NETs. In many patients, symptomatic relief and 
stabilization of tumor growth are achieved after the 
treatment using SSAs. However, partial or com-
plete spontaneous tumor regression is considered a 
rare phenomenon, and therefore combined therapy 
using SSA featuring other therapy strategies are 
crucial to further enhance the clinical achievement 
in NETs patients (Uri, et al., 2018). 
 Currently, synergistic effects of combined 
therapy of SSA and PRRT (SSA–PRRT) have been 
reported. A retrospective observational study in 99 
patients with G1/G2 NETs suggested that the me-
dian PFS for sequence therapy with SSA–chemo-
therapy was 20 months, while for SSA–PRRT was 
30 months. Despite there was no statistical differ-
ence in PFS, those two sequence therapy provided 
higher PFS compared to SSA standard dose–SSA 
high dose (median PFS was not reached), but lower 
than SSA–everolimus (33 months). This study also 
showed that the number of side effects in patients 
was higher in SSA–everolimus and SSA–chemo-
therapy groups compared to SSA standard dose–
SSA high dose and SSA to PRRT groups (Faggiano, 
et al., 2019). Again, from a different retrospective 
observational study in 168 patients with GEPNETs, 
it was found that the median PFS for PRRT was 27 
months in group I (PRRT monotherapy). Interest-
ingly, the median PFS was increased to 48 months 
in group II when SSA was combined with PRRT 
(Yordanova, et al., 2018).        
 Furthermore, combined therapy using che-
motherapy and PRRT (chemo–PRRT) has become 
an interesting therapeutic option for patients with 
advanced or relatively aggressive behaving meta-
static NETs, especially when it is unlikely to achieve 
favorable response to a single treatment strategy 
(Basu, et al., 2016). The synergistic effect of com-
bined PRRT using 177Lu–DOTA¬–TATE with che-
motherapeutics agents capecitabine + temozolo-
mide (CAPTEM) was reported in 30 patients with 
inoperable G1/G2, progressive, functional or non-
functional pNET. In this study, the median PFS was 
48 months, while overall response rate (ORR) and 
disease control rate (DCR) were 80% and 100%, 
respectively (Ramage, et al., 2018). These results 
suggest that combined therapy using chemo–PRRT 
is likely to increase the PFS in patients rather than 
single treatment with chemotherapy or PRRT alone. 
Moreover, in vivo study in mice bearing SSTR–ex-
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pressing H69 demonstrated that chemo-PRRT us-
ing TMZ and 177Lu-octreotate resulted in tumor size 
reduction. 
 Despite chemo–PRRT has shown encour-
aging results, negative interactions between the 
two treatments should be taken into consideration. 
For instance, chemotherapy agents might influence 
the SSTR–2 (PRRT target) expression on tumor 
cells. Additionally, tumor vasculature might be af-
fected by chemotherapy whereas adequate tumor 
perfusion is required for local biodistribution and 
accumulation of PRRT agent (Bison, et al., 2015). 
Furthermore, in a study by Brieau, et al., a high 
occurrence of myelodysplastic syndrome (MDS) 
and acute myeloid leukemia (AML) in GEPNETs 
patients treated with PRRT after previous chemo-
therapy with alkylating agents were observed. This 
study suggests that the importance of previous 
chemotherapy before PRRT should be considered 
(Brieau, et al., 2016). 
CONCLUSION
 The management of NETs poses a serious 
challenge due to the heterogeneous clinical pre-
sentations and varying degree of aggressiveness. 
Therefore, the application of a combined treatment 
using two or more strategies may become a better 
option. More importantly, the treatment approach 
for NETs patients should be individualized based 
on each tumor characteristics. Over the last few 
years, some advanced managements strategies have 
been explored, including the treatment using SSAs. 
More recently, SSAs have also been used in PRRT 
strategy, especially for the treatment of inopera-
ble or metastasized NETs. These strategies play an 
important role and have been proved as advanced 
techniques for treating NETs. Moreover, treatment 
using the combination of SSAs and PRRT or che-
motherapy and PRRT showed encouraging outcome 
for the patients as compared with single treatment 
either using SSAs, chemotherapy or PRTT alone. 
As a result, NETs management based on SSAs has 
increased and likely to become a continuing trend 
in routine clinical practice. More in–depth study, 
however, is needed to further understanding the role 
of SSAs in the treatment of NETs.  
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